SCHEMBL5540288

SCHEMBL5540288

[CH2]N1CCC(Oc2cccc(C)c2)CC1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.55
SLC6A4 P31645 1/20 0.55
SLC6A3 Q01959 1/20 0.55
EPHX2 P34913 1/20 0.49
ALDH1A1 P00352 2/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
ACHE P22303 1/20 0.43
NAAA Q02083 1/20 0.42
ACSL1 P33121 1/20 0.41
HRH3 Q9Y5N1 1/20 0.40
HRH1 P35367 1/20 0.40
CCR3 P51677 1/20 0.40
FPR2 P25090 1/20 0.39
PROKR1 Q8TCW9 1/20 0.39
OPRK1 P41145 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5540295 0.85 SLC6A2 (0.56) SLC6A2SLC6A4SLC6A3EPHX2MEN1
SCHEMBL12127336 0.84 SLC6A2 (0.67) SLC6A2SLC6A4SLC6A3EPHX2ALDH1A1
SCHEMBL22188038 0.84 SLC6A2 (0.55) SLC6A2SLC6A4SLC6A3EPHX2ALDH1A1
SCHEMBL20069655 0.84 SLC6A2 (0.55) SLC6A2SLC6A4SLC6A3EPHX2ALDH1A1
SCHEMBL12377875 0.81 HRH3 (0.54) SLC6A2SLC6A4SLC6A3EPHX2HRH3
SCHEMBL13855679 0.81 SLC6A2 (0.52) SLC6A2SLC6A4SLC6A3EPHX2ALDH1A1
SCHEMBL20069659 0.81 SLC6A2 (0.56) SLC6A2SLC6A4SLC6A3EPHX2ALDH1A1
SCHEMBL8352183 0.81 SLC6A2 (0.63) SLC6A2SLC6A4SLC6A3EPHX2ALDH1A1
SCHEMBL12127337 0.81 SLC6A2 (0.63) SLC6A2SLC6A4SLC6A3EPHX2ALDH1A1
SCHEMBL10262282 0.81 SLC6A2 (0.55) SLC6A2SLC6A4SLC6A3EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 SLC6A2 3396/4885SLC6A4 4191/4885SLC6A3 1944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.